Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.80 |
| ▸ | ILK | Q13418 | 3/20 | 0.80 |
| ▸ | KDR | P35968 | 4/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.68 |
| ▸ | FLT1 | P17948 | 2/20 | 0.68 |
| ▸ | KDM1A | O60341 | 2/20 | 0.68 |
| ▸ | GAK | O14976 | 2/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.68 |
| ▸ | CIT | O14578 | 1/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.68 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.68 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | BUB1 | O43683 | 1/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.68 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.68 |
| ▸ | STK17B | O94768 | 1/20 | 0.68 |
| ▸ | STK10 | O94804 | 1/20 | 0.68 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23264520 | 0.89 | EGFR (1.00) | EGFRILKKDRERBB2FLT1 | |
| SCHEMBL13646413 | 0.88 | EGFR (0.63) | EGFRILKKDRERBB2FLT1 | |
| SCHEMBL14481882 | 0.88 | EGFR (0.80) | EGFRILKKDRERBB2FLT1 | |
| SCHEMBL1507449 | 0.88 | EGFR (0.80) | EGFRILKKDRERBB2FLT1 | |
| SCHEMBL2615523 | 0.88 | EGFR (0.80) | EGFRILKKDRERBB2FLT1 | |
| Hydrochloric Acid SCHEMBL1507642 | 0.87 | EGFR (0.78) | EGFRILKKDRERBB2FLT1 | |
| SCHEMBL3871041 | 0.85 | EGFR (0.59) | EGFRILKKDRERBB2FLT1 | |
| SCHEMBL12426808 | 0.84 | HDAC3 (0.69) | EGFRILKKDRERBB2GAK | |
| SCHEMBL13219733 | 0.84 | EGFR (0.78) | EGFRILKKDRERBB2FLT1 | |
| SCHEMBL12426807 | 0.84 | HDAC3 (0.70) | EGFRKDRERBB2GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009121042-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | EGFR 19/4885ILK 2741/4885KDR 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.